News
Quizartinib (AC220) in Patients With FLT3-ITD(+) Relapsed or Refractory Acute Myeloid Leukemia: Final Results of a Randomized Phase 2 Study
Background FLT3-ITD in AML is associated with early relapse and poor survival after treatment with standard chemotherapy Quizartinib is an orally active FLT3-ITD inhibitor A previous Phase 2 study included subjects with FLT3-ITD(+) AML, relapsed/refractory to 2nd line chemotherapy or relapsed after hematopoietic stem cell transplant (HSCT), doses of 90, 135 or 200 mg/day – 46% of subjects achieved CRc (CRc = CR + CRp + CRi) – 35% of subjects were bridged to HSCT (mostly after achieving CRi) –…
A small molecule–kinase interaction map for clinical kinase inhibitors
Kinase inhibitors show great promise as a new class of therapeutics. Here we describe an efficient way to determine kinase inhibitor specificity by measuring binding of small molecules to the ATP site of kinases. We have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clinical development, against a panel of 119 protein kinases. We find that specificity varies widely and is not strongly correlated with chemical structure or the identity of the intended target. Many novel…
Ambit in the Media
BioWorld Today discusses Ambit’s Series D Financing – November 2007 In a frontpage article focused on Ambit’s $43.9 million Series D Financing, BioWorld Today discusses the company’s new and existing investors as well as its kinase inhibitor programs and new additions to its board of directors. Access the full article [64KB] bizSanDiego features the history of Ambit Biosciences and gets up close and personal with CEO, Scott Salka – January 2007 In its January cover story, bizSanDiego examines the history of…
Announcing the 2006 Fierce 15
FierceBiotech, April 2006 If you look over the biotech companies on this year’s list, you’ll see a few common attributes: There’s a big emphasis on efficient use of capital; more of these up-and-coming biotechs are striking licensing deals with major pharma partners at an earlier stage than ever; and the valuations they appear to be getting are strong. If you’ve got good science, there’s never been a better time to be a biotechnology company. Over the rest of the year,…